• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

Chagas disease: Bridging the gap between patients and treatment

Home > Viewpoints

Chagas disease: Bridging the gap between patients and treatment

Carolina Batista examines a Chagas patient.
23 Feb 2016
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

cbatista_1Viewpoint by

Carolina Batista, Regional Medical Director, DNDi Latin America

Just before the end of 2015, the notorious announcement of the acquisition of benznidazole rights in the USA with the intention to apply for the FDA’s Priority Review Voucher (PRV) has generated innumerous debates and certainly has driven worldwide attention to Chagas. This state of affairs, despite all the buzz around KaloBios’s former CEO, has exposed the dramatic treatment access situation regarding the leading parasitic killer of the Americas. Currently, 99% of the estimated patients endure the lack of diagnostic and medical attention according to PAHO recommendations.

The truth is that despite some advances in the Chagas landscape in the last years, no significant changes in access occurred and major gaps remain between the estimates of the number of people living with Chagas disease and those actually diagnosed and treated.

According to the latest WHO report, approximately 5.7 million people are infected by Chagas disease in Latin America, approximately 30% of which will develop a chronic heart condition that is estimated to cause more than 7,000 deaths annually. Chagas disease causes the highest disease burden of any parasitic disease in the Western hemisphere. Despite the reduction of new cases due to successful vector control and blood safety measures in Latin America, strong emphasis needs to be placed on scaling up diagnosis and treatment.

In an attempt to contribute to changing this paradigm and address current  challenges, DNDi has been working with local partners to identify the most appropriate context-specific access strategies and delivery models to scale up access to diagnosis and treatment in Chagas disease.

The process started with the consolidation of available baseline information, revision of country morbidity and mortality data, epidemiological profile, and overall assessment of current policies and basic regulatory aspects of Chagas disease. The first selected countries or regions were Colombia, Mexico, Brazil, the Gran Chaco, and the USA. Aligned with the Global Chagas Coalition, Ministries of Health, academia, international organizations, and other key stakeholders, the objective is to implement country-specific collaborative pilot projects, applying available tools and assessing the feasibility of implementing diagnosis and treatment for infected individuals in selected health centres, and of course to measure the impact. Furthermore, local communities are being engaged and specific health education activities are conducted to mobilize sustainable social support.

The first initiative was launched in Colombia, where DNDi and the Ministry of Health organized a joint seminar in April 2015 to discuss the elimination of barriers to diagnose and treat Chagas disease patients in Colombia. One of the most important outcomes of this meeting was the future collaboration among DNDi, the National Programme and the Colombian Network ‘Red Chagas’ to create the pilot project to enable the implementation of the Chagas Road Map in priority high endemic municipalities.

Throughout the year of 2015, DNDi has worked to provide technical and operational support to the Colombian National Programme to structure the roadmap for those pilot projects. Four endemic areas have been prioritized to yield the operational activities, validated diagnostic protocol, cost-effectiveness studies, and registration of benznidazole, as well as to establish indicators for Chagas disease:  Boyacá, Casanare, Arauca, and Santander.

In 2016, the aim is to conduct this Deployment Project also in the USA and Mexico. In each locality, synergies are fostered in such a way as to capitalize on local efforts and expertise to set up a model that works optimally in each environment and is designed to be replicated. Ultimately, the success of this project depends on multi-sectorial collaboration to ensure that far from the headlines of international financial dailies, the needs of patients are being addressed with what is available now, while R&D investment and efforts are being exerted to provide new tools to patients as soon as they become available.

Carolina Batista, Regional Medical Director, DNDi Latin America

[Español] [Português]

Chagas disease

Read, watch, share

Loading...
Lab activities
Press releases
29 Jun 2022

DNDi welcomes new PAHO recommendations for the treatment of leishmaniasis in the Americas

Publications
16 Jun 2022

DNDi‘s Commitment to the Kigali Declaration

Caregiver prepares 4-in-1 HIV treatment for child
Press releases
14 Jun 2022

Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa

Nurse with HIV-VL patient
Publications
8 Jun 2022

The Science Explained: Evaluating new treatment regimens for visceral leishmaniasis in people living with HIV in India and Ethiopia

Doctor with a patient
Press releases
8 Jun 2022

New WHO treatment guidelines offer hope for people co-infected with visceral leishmaniasis and HIV

Doctor talking with patient during a consultation
Press releases
1 Jun 2022

Thai partners unite with DNDi to improve access to treatments and diagnostics for people with hepatitis C in Thailand

Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

DNDi briefing document: Best science for all

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesNo description
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
_hjSessionUser_11288441 yearNo description
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo